This medical products company has seen one positive and one negative estimate revision over the last 30 days while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for GW Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent move higher can turn into more strength down the road.
GW Pharmaceuticals has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Some better-ranked stocks in the same industry include Enzymotec Ltd. (ENZY), Covidien plc (COV) and SurModics, Inc. (SRDX). While Enzymotec holds a Zacks Rank #1 (Strong Buy), Covidien and SurModics carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment